Malignant tumors
Conditions
Interventions
Sponsors
Changzhou Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 75 years old, gender not limited; 2.Malignant tumor patients requiring treatment with apatinib mesylate; 3.Patients who have not used apatinib mesylate tablets within the past week; 4.Patients who voluntary signing of informed consent form and have good treatment compliance.
Exclusion criteria
Exclusion criteria: 1.Patients who have developed gastrointestinal diseases such as gastric ulcers, constipation, intestinal obstruction, and diarrhea in the past month and are currently using relevant medications for treatment; 2.Patients currently taking proton pump inhibitors and other antacids; 3.Patients with concurrent other chronic diseases that require long-term medication, and the researchers believe that patients who are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of apatinib mesylate in human blood; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters; | — |
Countries
China
Contacts
Public ContactGuangzhao He
Changzhou Cancer Hospital
Outcome results
None listed